Allergan Acquires Elastagen to Help Create More Juvederm Products
- Posted on: Mar 8 2018
Allergan, the makers of Juvederm and Botox, have announced the acquisition of the Australian company, Elastagen, whose technology helps generate elastin in the skin.
Elastin production in the skin can help minimize the appearance of scars, fine lines, stretch marks, wound repair, and is a key component in bright, youthful skin. Their “tropoelastin” is identical to the elastin in human tissue, therefore, works well to deliver results and is an exciting development in the aesthetic market.
This partnership is likely to result in a new line of Juvederm products, utilizing a new “Rejuvecross” technology, similar to the Vycross and Hylacross technologies used for many other Juvederm products, such as Voluma, Vollure, and Volbella.
“Our Juvederm collection of fillers has sales of over $1 billion globally and is one of the fastest growing parts of our Aesthetics business,” said Bill Meury, CCO at Allergan. “This acquisition and the development of a next generation of injectables based on this technology will ensure Allergan offers innovative filler products for years to come.”
Utah Facial Plastics is of the top 2.4% of Juvederm and Botox providers in entire nation and use all fillers from the Juvederm family multiple times daily, such as Juvederm Ultra, Ultra Plus, Voluma, Volbella and Vollure. The addition of Juvederm products will only allow their expert injectors to offer more amazing options for facial rejuvenation.
For more information, see the full press release here.